Crinetics Pharmaceuticals Inc.
19
7
10
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
21%
4 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
Role: lead
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Role: lead
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Role: lead
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Role: lead
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Role: lead
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Role: lead
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Role: lead
A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
Role: lead
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Role: lead
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Role: lead
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Role: lead
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
Role: lead
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Role: lead
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Role: lead
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
Role: lead
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
Role: lead
A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers
Role: lead
Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers
Role: lead
Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers
Role: lead
All 19 trials loaded